Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis F. KoohiT. KazemiE. Miri-Moghaddam Review Article 07 February 2019 Pages: 1323 - 1331
Prevalence of extramedullary hematopoiesis, renal cysts, splenic and hepatic lesions, and vertebral hemangiomas among thalassemic patients: a retrospective study from the Myocardial Iron Overload in Thalassemia (MIOT) network Paolo RicchiAntonella MeloniAlessia Pepe Original Article 20 March 2019 Pages: 1333 - 1339
Use of eltrombopag in aplastic anemia in Europe Matyas EcsediÉtienne Lenglinefor the EBMT SAA Working Party Original Article 26 March 2019 Pages: 1341 - 1350
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study N. J. AmesJ. J. BarbG. R. Wallen Original Article 27 March 2019 Pages: 1351 - 1365
Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60–69 years with myelodysplastic syndrome Hidehiro ItonagaKen IshiyamaYasushi Miyazaki Original Article 11 March 2019 Pages: 1367 - 1381
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome Panagiotis T. DiamantopoulosChristina-Nefeli KontandreopoulouOn behalf of the Hellenic MDS Study Group Original Article 15 March 2019 Pages: 1383 - 1392
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) Torsten KesslerSteffen KoschmiederWolfgang E. Berdel Original Article 21 March 2019 Pages: 1393 - 1401
Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country Mecneide Mendes LinsMaria Julia Gonçalves MelloLuiz Claudio Santos Thuler Original Article 26 March 2019 Pages: 1403 - 1411
A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots Bettina KáraiMira HabókZsuzsanna Hevessy Original Article Open access 04 March 2019 Pages: 1413 - 1420
Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis T. DemuynckG. VerhoefTimothy Devos Original Article 27 March 2019 Pages: 1421 - 1426
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome Georgia TrakadaEfstathios KastritisMeletios A. Dimopoulos Original Article 05 March 2019 Pages: 1427 - 1434
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study Maxime JullienSabrina TrudelCyrille Touzeau Original Article 14 March 2019 Pages: 1435 - 1440
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study Sabrina TrudelBenoît TessoulinCyrille Touzeau Original Article 14 March 2019 Pages: 1441 - 1447
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients Francesco GaudioPatrizio MazzaGiorgina Specchia Original Article 14 March 2019 Pages: 1449 - 1455
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome Christina HadjiaggelidouEvdokia MandalaEirini Katodritou Original Article 20 March 2019 Pages: 1457 - 1466
The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage Linshu ZengWenting HuangXiaoli Feng Original Article 21 March 2019 Pages: 1467 - 1476
Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience Grzegorz HelbigAdrianna SpałekAnna Koclęga Original Article Open access 27 March 2019 Pages: 1477 - 1483
Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study Yves SoltermannDominik HeimMartina Kleber Original Article 26 March 2019 Pages: 1485 - 1493
Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience Elisabetta MetafuniMarianna CriscuoloSimona Sica Letter to the Editor 01 November 2018 Pages: 1495 - 1497
Retrospective analysis of thiamine deficiency in allogeneic stem cell transplant patients Hannah LevaviDoyun ParkAmir Steinberg Letter to the Editor 03 November 2018 Pages: 1499 - 1500
Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy Masako YokooKensuke KojimaShinya Kimura Letter to the Editor 08 November 2018 Pages: 1501 - 1503
Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma Alessandra SerraoMartina CanichellaAlessandro Pulsoni Letter to the Editor 09 November 2018 Pages: 1505 - 1506
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis Giovanni MartinoAndrea MarraPaolo Sportoletti Letter to the Editor 13 November 2018 Pages: 1507 - 1508
Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia Vlatko PejsaMarko LucijanicGorana Vukorepa Letter to the Editor 13 November 2018 Pages: 1509 - 1510
Diffuse large B cell lymphoma and schistosomiasis: a rare simultaneous occurrence Magda ZanelliMaurizio ZizzoStefano Ascani Letter to the Editor 19 November 2018 Pages: 1511 - 1512
Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence? Simon HaefligerDina MilowichLaurence de Leval Letter to the Editor 28 November 2018 Pages: 1513 - 1516
Synchronous follicular non-Hodgkin’s lymphoma and hairy cell leukaemia: a case report Laura McDonaldK. Fadalla Letter to the Editor 04 December 2018 Pages: 1517 - 1518
Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma Wolfgang LammBarbara KiesewetterMarkus Raderer Letter to the Editor 13 December 2018 Pages: 1519 - 1520
Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma Satoshi YamasakiDai ChiharaRitsuro Suzuki Letter to the Editor 17 December 2018 Pages: 1521 - 1523
Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm Chunli YangChunxi FuLiqun Zou Letter to the Editor 29 January 2019 Pages: 1525 - 1527
Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation Kristian BoasmanMatthew James SimmondsCiro Roberto Rinaldi Letter to the Editor 05 February 2019 Pages: 1529 - 1531
Inhibitor eradication in refractory acquired hemophilia with lenalidomide C. PfrepperW. PoenischS. Petros Letter to the Editor 01 February 2019 Pages: 1533 - 1535